Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal https://lnkd.in/ennbUets
About us
- Website
-
https://www.pesgresearch.com/
External link for PESG Research
- Industry
- Market Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at PESG Research
Updates
-
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs. https://lnkd.in/dPE_RYex
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential - Thermo Fisher Scientific (NYSE:TMO)
benzinga.com
-
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential https://lnkd.in/dMFw2KEd
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential - Bristol-Myers Squibb (NYSE:BMY)
benzinga.com
-
Stop ripping us off’: Novo Nordisk CEO faces Senate grilling over weight loss drug prices https://lnkd.in/dqSKNKNr
'Stop ripping us off': Novo Nordisk CEO faces Senate grilling over weight loss drug prices
cnbc.com
-
Appeals Court Breathes New Life Into PhRMA’s Legal Challenge to IRA https://lnkd.in/dJjYGJSV
Appeals Court Breathes New Life Into PhRMA’s Legal Challenge to IRA
biospace.com
-
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure https://lnkd.in/dm3AhasR
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure - Novo Nordisk (NYSE:NVO)
benzinga.com
-
FDA Approves Merck’s Keytruda for First-Line Treatment of Pleural Mesothelioma https://lnkd.in/d9jR9EjK
FDA Approves Merck’s Keytruda for First-Line Treatment of Pleural Mesothelioma
biospace.com
-
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028 https://lnkd.in/dAV7U9kN
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028
biospace.com
-
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs https://lnkd.in/dbHuyTV6
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
fiercebiotech.com
-
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections https://lnkd.in/de8J53dY
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections - Gilead Sciences (NASDAQ:GILD)
benzinga.com